Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya

by Doreen Lugano, Bernadette Kutima, Makobu Kimani, Antipa Sigilai, John Gitonga, Angela Karani,, Donald Akech, Boniface Karia, Abdhalah K. Ziraba, Angela Maina, Arnold Lambisia, Donwilliams Omuoyo, Daisy Mugo, Ruth Lucinde, Sharon Owuor, Gloria Konyino, Joseph Newman, Dalan Bailey,, Eunice Nduati, George Githinji, Charles N. Agoti, Philip Bejon, J. Anthony G. Scott,, Ambrose Agweyu, Wangeci Kagucia, George M. Warimwe, Charles Sande, Lynette I. Ochola-Oyier, James Nyagwange
10th January 2025 • comment

Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation

by Alex Sigal et al
22nd April 2024 • comment

Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant

by Alex Sigal et al
22nd April 2024 • comment

Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant

by Julia Stowe et al.

We recently reported vaccine effectiveness (VE) estimates against symptomatic disease with the Delta (B.1.617.2) variant.(1) After a full course, VE reached 88% with the Pfizer/BioNTech BNT162b2 vaccine and 67% with the AstraZeneca ChAdOx1 AZD1222 vaccine. This provided important evidence that despite modest reductions in protection, vaccines remain effective against Delta. However, the very recent emergence of the variant and the relatively low case numbers meant that it was not possible to estimate VE against severe disease.

14th June 2021 • comment